Moderna
MRNA
$142.81
Share price
0.44%
Change (1 day)
-35.94%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.
Revenue for Moderna (MRNA)
Revenue in 2022 (TTM): $22.60 B
According to Moderna 's latest financial reports the company's current revenue (TTM) is $22.60 B. In 2021 the company made a revenue of $18.47 B an increase over the years 2020 revenue that were of $0.80 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Moderna from 2018 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | $22.60 B | 22.35% |
| 2021 | $18.47 B | 2199.12% |
| 2020 | $0.80 B | 1234.34% |
| 2019 | $0.06 B | -55.42% |
| 2018 | $0.13 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $94.88 B | 319.82% | 🇺🇸 USA |
 Novartis NVS | $51.74 B | 128.96% | 🇨🇭 Switzerland |
 Merck MRK | $53.97 B | 138.84% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | N/A | -100.00% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | $0.19 B | -99.15% | 🇺🇸 USA |
 Athersys ATHX | $8.42 M | -99.96% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $0.87 B | -96.11% | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | $0.26 B | -98.83% | 🇺🇸 USA |